Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program

Stuart H. Cohen; Paul R Allyn; Felicia C. Chow; Jennifer Rathe; Deepa Dharshani Nanayakkara; Gerald Hutfles; Tara Vijayan; Christopher F. Saling; Dan Ilges; Haran T. Schlamm; George R. Thompson

doi:10.1093/cid/ciag271

Enriched recordOpen access

Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program

Stuart H. Cohen, Paul R Allyn, Felicia C. Chow, Jennifer Rathe, Deepa Dharshani Nanayakkara, Gerald Hutfles, Tara Vijayan, Christopher F. Saling, Dan Ilges, Haran T. Schlamm, George R. Thompson

Clinical Infectious Diseases2026doi:10.1093/cid/ciag271

Citation graph

Abstract

Abstract Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix (“gepix”), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; nonmeningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.

Authors

Stuart H. Cohen#1 Paul R Allyn#2 Felicia C. Chow#3 Jennifer Rathe#4 Deepa Dharshani Nanayakkara#5 Gerald Hutfles#6 Tara Vijayan#7 Christopher F. Saling#9 Dan Ilges#10 Haran T. Schlamm

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology

10.1016/s1473-3099(21)00191-2 · 2021

The geographic distribution of dimorphic mycoses in the United States for the modern era

10.1093/cid/ciac882 · 2023

Surveillance for coccidioidomycosis, histoplasmosis, and blastomycosis—United States, 2019

2022

Tolerability of long-term fluconazole therapy

10.1093/jac/dky501 · 2019

Large-scale evaluation of in vitro amphotericin B, triazole, and echinocandin activity against coccidioides species from U.S. institutions

10.1128/aac.02634-16 · 2017

Isavuconazole in the treatment of chronic forms of coccidioidomycosis

10.1093/cid/ciad146 · 2023

Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis

10.1093/mmy/myy029 · 2019

Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal nfections

10.3390/jof6040239 · 2020

Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers

Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program

Referenced works

Cited by

External reference records

Additional external references